



Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Maryam Edalatifard^{1,17}, Maryam Akhtari ^{2,3,17}, Mohammadreza Salehi⁴, Zohre Naderi ⁵, Ahmadreza Jamshidi^{2,18}, Shayan Mostafaei⁶, Seyed Reza Najafizadeh ⁷, Elham Farhadi^{2,3}, Nooshin Jalili⁸, Masoud Esfahani⁹, Besharat Rahimi¹, Hossein Kazemzadeh¹, Maedeh Mahmoodi Aliabadi¹⁰, Tooba Ghazanfari¹¹, Mohammadreza Sattarian¹², Hourvash Ebrahimi Louyeh¹³, Seyed Reza Raeeskarami¹⁴, Saeidreza Jamalimoghadamsiahkali¹⁵, Nasim Khajavirad¹⁶, Mahdi Mahmoudi ^{2,3,18} and Abdolrahman Rostamian^{7,18}

@ERSpublications

This study showed that methylprednisolone pulse administration at the beginning of the early pulmonary phase of illness decreased the mortality rate and improved pulmonary involvement, oxygen saturation and inflammatory markers in COVID-19 patients <https://bit.ly/3hik4JB>

Cite this article as: Edalatifard M, Akhtari M, Salehi M, *et al.* Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. *Eur Respir J* 2020; 56: 2002808 [<https://doi.org/10.1183/13993003.02808-2020>].

ABSTRACT

Introduction: There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.

Methods: We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day⁻¹ for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.

Results: 68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1% *versus* 57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9% *versus* 42.9%; $p < 0.001$). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: $p < 0.001$; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.

Conclusions: Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.

The study is registered at the Iranian Registry of Clinical Trials with identifier IRCT20200404046947N1.

This article has an editorial commentary: <https://doi.org/10.1183/13993003.04116-2020>

This article has supplementary material available from ersjournals.com

Received: 16 July 2020 | Accepted after revision: 7 Sept 2020

Copyright ©ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Introduction

The world is experiencing the pandemic of a novel coronavirus-induced respiratory illness named COVID-19. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the genus Betacoronavirus [1]. Betacoronaviruses are positive single-stranded RNA viruses that have caused two other severe outbreaks, *i.e.* Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), over recent decades [2]. COVID-19 has rapidly spread across the world and the number of infected people is increasing since it was first discovered in China in late 2019. The virus can be transmitted from person to person during the 2–14-day asymptomatic incubation period. The signs of illness range from fever, dry cough, fatigue, myalgia and mild respiratory tract symptoms to severe manifestations, including shortness of breath, pneumonia and acute respiratory distress syndrome (ARDS), dependent on the patient's age, genetics factors and the function of the immune system [3, 4]. Extrapulmonary involvements (*e.g.* hepatic and gastrointestinal) are also present in some patients [5].

Typically, in the early phase of the disease, specific and proper immune system responses eliminate virus reproduction and prevent disease progression to the hyperinflammation phase. If the infection is not eliminated by the appropriate and strong immune responses, the disease enters the severe inflammatory response phase when a cytokine storm and elevated inflammatory markers produced by innate immune cells induce pulmonary fibrosis, shortness of breath, reduction in oxygen saturation and systemic injuries, resulting in ARDS and the patient's death [6]. Cytokine storm induction by SARS-CoV-2 was confirmed in COVID-19 patients in the intensive care unit (ICU), and elevated plasma levels of inflammatory cytokines have been associated with disease severity and prognosis [7, 8].

ARDS is the main reason for death in COVID-19 patients and there are no efficient specific treatment agents for the disease [8]. It is suggested that glucocorticoids and immunosuppressive treatment can reduce the inflammation of the respiratory system and prevent the cytokine storm and ARDS induction in COVID-19 patients [9]. Methylprednisolone is a glucocorticoid medication used to suppress autoimmune and inflammatory responses in rheumatic diseases [10]. Previously, methylprednisolone was administered in SARS and MERS patients, and the results were controversial [11–13]; however, glucocorticoid administration in COVID-19 patients in the hyperinflammation stage is likely to have survival benefits due to cytokine storm suppression. Hence, in this study, we investigated the methylprednisolone pulse effect as a glucocorticoid therapy on the treatment, clinical symptoms and laboratory signs of hospitalised severe COVID-19 patients.

Patients and methods

Study design

This study was conducted as a single-blind, two-arm parallel, randomised controlled trial from April 20, 2020 to June 20, 2020. We enrolled 68 subjects from the Imam Khomeini Hospital, Tehran University of Medical Sciences (Tehran, Iran) and Khorshid Hospital, Isfahan University of Medical Sciences (Isfahan, Iran). The study protocol was written and mediated in accordance with the CONSORT (Consolidated Standards of Reporting Trials) statement [14] and the study was registered at the Iranian Registry of Clinical Trials on April 15, 2020 with identifier IRCT20200404046947N1. Since there are no published clinical trials on the effect of methylprednisolone in patients with COVID-19, the minimum sample size was estimated as 60 plus 10% potential missing data based on the effect size of methylprednisolone on pulmonary and lung function diseases [15–17].

Affiliations: ¹Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³Inflammation Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁴Dept of Infectious and Tropical Medicines, Tehran University of Medical Sciences, Tehran, Iran. ⁵Dept of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ⁶Dept of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ⁷Rheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. ⁸Dept of Internal Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. ⁹Dept of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ¹⁰Dept of Laboratory, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. ¹¹Immunoregulation Research Center, Shahed University, Tehran, Iran. ¹²Simorgh Clinical Laboratory, Tehran, Iran. ¹³Dept of Rheumatology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. ¹⁴Dept of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran. ¹⁵Ziaei Hospital, Tehran University of Medical Sciences, Tehran, Iran. ¹⁶Dept of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ¹⁷These two authors contributed equally as first authors. ¹⁸These three authors contributed equally as lead authors and supervised the work.

Correspondence: Abdolrahman Rostamian, Rheumatology Research Center, Imam Khomeini Hospital, PO Box 1418419967, Tehran, Iran. E-mail: arostamian@tums.ac.ir

This trial was performed based on the Declaration of Helsinki guidelines and was approved by the Ethics Committee of Tehran University of Medical Sciences (approval IR.TUMS.VCR.REC.1399.054).

Patients

The diagnosis of COVID-19 in subjects was performed based on the following criteria: 1) identification of SARS-CoV-2 via reverse transcription-PCR in nasopharyngeal swab or sputum samples and 2) abnormal computed tomography (CT) scan findings (bilateral, subpleural, peripheral ground-glass opacities) with blood arterial oxygen saturation measured by pulse oximetry (S_{pO_2}) <90% at rest. The early pulmonary phase was defined as the start of pulmonary involvement, including hypoxia (S_{pO_2} <93%), tachypnoea (respiratory rate >18 breaths·min⁻¹) and little dyspnoea, and based on CT scan findings. All patients signed informed consent before being enrolled in the study.

Inclusion criteria

Patients were included in the study if they met the following criteria: 1) aged ≥18 years, 2) confirmed COVID-19 with S_{pO_2} <90%, elevated C-reactive protein (CRP) (>10 mg·L⁻¹) and interleukin (IL)-6 (>6 pg·mL⁻¹) at the early pulmonary phase of disease before connecting to the ventilator and intubation, and 3) agreed to give informed consent (figure 1).

Exclusion criteria

Individuals were excluded from the study if they met the following criteria: 1) intolerant or allergic to any therapeutic agents used in this research, 2) pregnant or lactating females, and 3) S_{pO_2} <75%, positive pro-calcitonin (PCT) and troponin test, ARDS, uncontrolled hypertension, uncontrolled diabetes mellitus, gastrointestinal problems or gastrointestinal bleeding history, heart failure, active malignancies or received any immunosuppressor agents.

Randomisation and masking

Once eligibility had been confirmed (24–48 h after hospitalisation), the patients were randomly allocated to control (n=34) and intervention (n=34) groups in a 1:1 ratio by the block randomisation method.




FIGURE 1 Appropriate time for methylprednisolone administration and inclusion/exclusion criteria of the patients. Patients in the intervention group received methylprednisolone pulse (intravenous injection, 250 mg·day⁻¹ for 3 days) at the early pulmonary phase of the disease before connection to the ventilator and intubation. ICU: intensive care unit; S_{pO_2} : arterial oxygen saturation measured by pulse oximetry; CRP: C-reactive protein; IL: interleukin; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; PCT: pro-calcitonin; ARDS: acute respiratory distress syndrome; GI: gastrointestinal.

Patients were allocated to either receive methylprednisolone pulse (intravenous injection, 250 mg·day⁻¹ for 3 days) or not receive methylprednisolone/other glucocorticoids. All patients received standard care (hydroxychloroquine sulfate, lopinavir and naproxen) for COVID-19 according to the protocol for diagnosis and treatment of COVID-19 in Iran. Patients were blinded to the treatment group. Physicians and clinician teams knew about the medicine and intervention groups. Due to the emergency nature of this trial, placebos of methylprednisolone were not prepared.

Procedures and outcomes

Clinical and demographic characteristics of the study participants were obtained before enrolment in the study. All patients were followed-up from day 0 to day 3, improvement, hospital discharge or death and 1 week after hospital discharge, which was scheduled at three or four consecutive visit points. Clinical signs of the patients including heart rate, body temperature, blood pressure, S_{pO_2} , dyspnoea, cough, gastrointestinal involvement symptoms, myalgia, chest pain and Borg score were assessed before and after treatment (by 3 days of treatment and discharge time). The need for oxygen therapy (nasal cannula, mask oxygen, reservoir mask, noninvasive ventilation (NIV) and invasive ventilation) was recorded before and after treatment (by 3 days of treatment and discharge time). CT scan findings were also assessed before and 1 week after treatment only if patients agreed to give informed consent. Other clinical outcomes, including mortality rate, duration of hospitalisation in improved patients and the time from the initiation of treatment to death, were assessed in each group. Laboratory test results, including complete blood count, CRP, erythrocyte sedimentation rate, venous blood gas (VBG) analysis (including pH, bicarbonate (HCO_3^-) and partial pressure of carbon dioxide (PCO_2)), IL-6, ferritin, troponin, D-dimer, lactate dehydrogenase (LDH) and creatine phosphokinase (CPK), were recorded before and after treatment (by 3 days of treatment and discharge time). Clinical signs of the improved patients, including cough, gastrointestinal symptoms, myalgia, chest pain and Borg score, were assessed 1 week after discharge time.

All data were considered during the study and follow-up time, and recorded on case report forms and an Excel (Microsoft, Redmond, VA, USA) database. The primary end-points were the time of clinical improvement and time of discharge from the hospital or death, whichever came first. Hospital discharge was determined according to the patient's clinical and laboratory findings. Improvement was defined as Borg score >3, improved dyspnoea, no fever for 72 h, S_{pO_2} >93%, tolerated oral regime, normal urinary output and reduced CRP level without any treatment side-effects.

Adverse events

All undesirable effects (adverse events) experienced by patients during the study, whether or not related to methylprednisolone treatment, were defined and recorded.

Statistical analysis

Data are presented as means with standard deviations for continuous variables, unless otherwise stated. Categorical variables are presented as numbers and percentages. The Kolmogorov–Smirnov normality test was performed on all data. Repeated measures ANOVA was used for comparison of the trends over time between both groups for each studied variable. Moreover, the t-test (parametric) or Mann–Whitney test (nonparametric) was used to test for statistical differences (two-tailed) between two independent groups. The paired t-test (parametric) or Wilcoxon signed-rank test (nonparametric) was used to test for statistical differences between two time-points in each of the intervention groups. Two-sided Chi-squared/Fisher's exact tests were used to assess the associations between intervention groups and the categorical variables. Kaplan–Meier survival curve analysis and the log-rank test were used to analyse time to death between both intervention groups. After analysing the baseline data, using the intention-to-treat (ITT) test, multiple imputations were conducted by an expectation maximisation algorithm in order to make an unbiased comparison between intervention groups in handling missing data. The false discovery rate was corrected using the Benjamini–Hochberg correction method for multiple comparisons. All statistical analysis was performed using Stata version 11.2 (StataCorp, College Station, TX, USA). Statistical significance was considered at $p < 0.05$.

Results

Patients

Of the 68 patients who underwent randomisation, 34 patients were assigned to receive standard care and methylprednisolone, and 34 patients were assigned to standard care alone. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. Based on the per-protocol analysis, the results for the outcomes did not significantly differ from the results of the ITT analysis. Randomisation, enrolment and treatment assignment are described in figure 2. The age of patients was 58.5±16.6 years (23 (37.1%) females and 39 (62.9%) males).




FIGURE 2 Randomisation, enrolment and treatment assignment.

22 patients (35.5%) had a respiratory rate >24 breaths·min⁻¹ and 13 patients (21.0%) had a heart rate >100 beats·min⁻¹. Coexisting conditions and demographic and clinical characteristics in each group are shown in table 1. Respiratory rate and heart rate levels were significantly higher in the methylprednisolone group. Except for diabetic comorbidity, which was significantly higher in the standard care group, there were no major between-group differences in demographic and clinical characteristics at enrolment. The median±range interval between disease symptom onset and hospitalisation was 6.8 ± 3.0 days. S_{pO_2} and Borg score of patients were $82.7\pm 5.3\%$ and 7.4 ± 2.1 , respectively, at baseline. The majority of patients had 30–50% (24 (38.7%)) or 50–70% (19 (30.6%)) pulmonary involvement and all patients were receiving oxygen support. Table 2 shows status and pulmonary involvement level at baseline for the patients in each group. Except for the difference in the pulmonary involvement zone, there were no between-group differences in status and pulmonary involvement at enrolment.

Primary outcomes

Patients in the methylprednisolone group had a significantly reduced median±range time to event (discharge or death) compared with patients in the standard care group (11.62 ± 4.81 versus 17.61 ± 9.84 days; $p=0.006$). In addition, median±range time to improvement was significantly lower in the methylprednisolone group (11.84 ± 4.88 versus 16.44 ± 6.93 days; $p=0.011$) compared with the standard care group and methylprednisolone treatment was related to the shorter time to event in patients (table 3). The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (32 (94.1%) versus 16 (57.1%)) and the mortality rate was significantly lower in the methylprednisolone group (2 (5.9%) versus 12 (42.9%); $p<0.001$).

Using the Kaplan–Meier estimator of time to death, we demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: $p<0.001$; hazard ratio 0.293, 95% CI 0.154–0.556) (figure 3).

Incidence of death was significantly lower in patients receiving NIV, reservoir mask and nasal cannula support in the methylprednisolone group (7.7%, 8.3% and 0%, respectively) compared with the standard care group (60%, 57.1% and 22%, respectively) (supplementary figure S1). CT scan findings from all of the deceased patients in the methylprednisolone group ($n=2$) and 75% of the patients in the standard care group ($n=9$) showed bilateral ground-glass opacities at enrolment.

Secondary outcomes

S_{pO_2} and Borg score were significantly improved after 3 days of treatment and at discharge time in the methylprednisolone group, whereas S_{pO_2} was significantly decreased in the standard care group after 3 days

TABLE 1 Baseline demographic and clinical characteristics of patients at baseline

	Total	Methylprednisolone	Standard care	p-value
Subjects	62	34	28	
Age years	58.5±16.6	55.8±16.4	61.7±16.6	0.193
Sex				0.205
Male	39 (62.9)	24 (70.6)	15 (53.6)	
Female	23 (37.1)	10 (29.4)	13 (46.4)	
Coexisting conditions				
Diabetes	22 (35.5)	8 (23.5)	14 (50.0)	0.040*
Hypothyroidism	4 (6.5)	4 (11.8)	0	0.118
Cancer	3 (4.8)	1 (2.9)	2 (7.1)	0.590
Respiratory disorder	6 (9.7)	3 (8.8)	3 (10.7)	0.838
Renal disorder	7 (11.3)	3 (8.8)	4 (14.3)	0.532
Cardiovascular disorder	11 (17.7)	6 (17.6)	5 (17.9)	0.966
Hypertension	20 (32.3)	10 (29.4)	10 (35.7)	0.666
Autoimmune and neurodegenerative diseases	5 (8.1)	2 (5.9)	3 (10.7)	0.654
Body temperature C	37.3±0.8	37.4±0.9	37.2±0.8	0.356
Respiratory rate breaths·min⁻¹	22.6±4.6	23.7±4.6	21.4±4.5	0.048*
Respiratory rate >24 breaths·min⁻¹	22 (35.5)	16 (47.1)	6 (21.4)	0.028*
Heart rate beats·min⁻¹	89.7±14.8	93.9±13.2	84.6±15.3	0.010*
Heart rate >100 beats·min⁻¹	13 (21.0)	10 (29.4)	3 (10.7)	0.062
Systolic blood pressure mmHg	122.6±14.9	121.4±15.3	124.0±14.7	0.563
Systolic blood pressure <100 mmHg	0	0	0	NA
Diastolic blood pressure mmHg	75.6±8.6	76.1±9.4	75.3±7.7	0.643
Fever	32 (51.6)	17 (50.0)	15 (53.6)	0.891
Dyspnoea	39 (62.9)	23 (67.6)	16 (57.1)	0.310
GI symptoms	29 (46.8)	16 (47.1)	13 (46.4)	0.961
Myalgia	32 (51.6)	17 (50.0)	15 (53.6)	0.779
Headache	8 (12.9)	3 (8.8)	5 (17.9)	0.453
Cough	38 (61.3)	23 (67.6)	15 (53.6)	0.498
Weakness	17 (27.4)	9 (26.5)	8 (28.6)	0.921
WBC count ×10³ mg·L⁻¹	7.6±3.9	7.7±3.3	7.4±4.6	0.866
4–10	47 (75.8)	25 (73.5)	22 (78.6)	0.811
<4	7 (11.3)	4 (11.8)	3 (10.7)	0.893
>10	7 (11.3)	5 (14.7)	2 (7.1)	0.697
Lymphocyte count mg·L⁻¹	1169.0±597.1	1167.7±580.7	1170.7±632.4	0.866
800–5000	42 (67.7)	25 (73.5)	17 (60.7)	0.643
<800	16 (25.8)	9 (26.5)	7 (25.0)	0.811
>5000	0	0	0	NA
Platelet count ×10³ mg·L⁻¹	219.9±106.8	203.8±69.7	241.0±140.4	0.158
<150	10 (16.1)	6 (17.6)	4 (14.3)	0.426
150–450	49 (79.0)	28 (82.4)	21 (75.0)	0.513
>450	1 (1.6)	0	1 (3.8)	NA
Haemoglobin g·dL⁻¹	13.7±4.2	13.0±1.7	14.7±6.0	0.102
VBG analysis				
pH	7.40±0.04	7.42±0.05	7.39±0.03	0.046*
HCO ₃ mEq·L ⁻¹	24.4±5.6	25.5±4.7	22.9±6.4	0.096
P _{CO₂} mmHg	37.9±10.1	39.7±11.1	35.4±8.1	0.156
CRP mg·L⁻¹	96.1±75.2	99.1±80.0	92.6±70.3	0.707
ESR mm·h⁻¹	61.6±29.8	64.2±27.1	57.4±32.8	0.382
IL-6 pg·mL⁻¹	77.4±76.1	76.3±85.0	79.3±60.9	0.894
D-dimer ng·mL⁻¹	2053.3±2363.7	2573.5±2667.7	1391.3±1750.9	0.057
Ferritin ng·mL⁻¹	750.9±496.6	807.9±521.0	676.5±463.5	0.345
LDH U·L⁻¹	658.5±235.6	672.1±285.5	644.9±179.3	0.728
CPK U·L⁻¹	176.3±168.9	158.9±151.7	213.7±209.0	0.491
Troponin negative	63 (100)	34 (100)	28 (100)	NA
SARS-CoV-2 PCR positive	63 (100)	34 (100)	28 (100)	NA
PCT negative	63 (100)	34 (100)	28 (100)	NA

Data are presented as n, mean±SD or n (%), unless otherwise stated. GI: gastrointestinal; WBC: white blood cell; VBG: venous blood gas; P_{CO₂}: partial pressure of carbon dioxide; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; CPK: creatine phosphokinase; PCT: pro-calcitonin; NA: not available. *: p<0.05.

TABLE 2 Status and pulmonary involvement level of patients at baseline

	Total	Methylprednisolone	Standard care	p-value
Subjects	62	34	28	
Time from illness onset to hospitalisation days[#]	6.8±3.0	6.7±2.9	6.9±3.1	0.814
Borg score	7.4±2.1	7.7±1.7	7.1±2.6	0.182
S_{pO₂} %	82.7±5.3	82.0±5.8	83.6±4.7	0.267
Need for oxygen therapy	62 (100)	34 (100)	28 (100)	0.460
Type of oxygen therapy				
Nasal cannula	13 (21.0)	4 (11.8)	9 (32.1)	0.194
Simple mask	7 (11.3)	5 (14.7)	2 (7.1)	
Reservoir mask	18 (29.0)	12 (35.3)	6 (21.4)	
NIV	23 (37.1)	13 (38.2)	10 (35.7)	
Ground-glass opacity	53 (85.5)	30 (88.2)	23 (82.1)	0.334
Unilateral	0	0	0	NA
Bilateral	53 (100)	30 (100)	23 (100)	NA
Consolidation positive	43 (69.3)	23 (67.6)	20 (71.4)	0.911
Unilateral	6 (14.0)	3 (13.0)	3 (15.0)	0.977
Bilateral	37 (86.0)	20 (87.0)	17 (85.0)	
Pulmonary involvement				
A (<10%)	0	0	0	0.050
B (10–30%)	7 (11.3)	1 (2.9)	6 (21.4)	
C (30–50%)	24 (38.7)	13 (38.2)	11 (39.3)	
D (50–70%)	19 (30.6)	11 (32.4)	8 (28.6)	
E (>70%)	12 (19.4)	9 (26.5)	3 (10.7)	
Pulmonary involvement zone				
All	28 (44.4)	20 (58.8)	8 (28.6)	0.031*
Upper	5 (8.1)	3 (8.8)	2 (7.1)	0.728
Lower	23 (37.1)	10 (29.4)	13 (46.4)	0.104
Middle	18 (29.0)	11 (32.4)	7 (25.0)	0.649

Data are presented as n, mean±SD or n (%), unless otherwise stated. S_{pO₂}: arterial oxygen saturation measured by pulse oximetry; NIV: noninvasive ventilation; NA: not available. [#]: median±range. *: p<0.05.

of treatment and the increase of S_{pO₂} at discharge time was not significant in this group. The Borg score of patients did not change after 3 days of treatment in the standard care group and a significant decrease was only observed at discharge time in this group (table 4).

Heart rate and temperature were significantly decreased after 3 days of treatment and at discharge time only in the methylprednisolone group. Respiratory rate was also significantly reduced in the methylprednisolone group after treatment, whereas it was significantly increased in the standard care group after 3 days of treatment. Clinical characteristics of patients, including gastrointestinal symptoms, myalgia, chest pain and cough, were significantly improved in the methylprednisolone group after 3 days of treatment and at discharge time; however, chest pain and cough did not change significantly in the standard care group after treatment. Clinical characteristics of patients before and after treatment are shown in table 4.

Six out of 34 patients, by 3 days of treatment, and 26 out of 32 patients, at discharge time, did not need oxygen support in the methylprednisolone group. In the standard care group, two out of 28 patients, by

TABLE 3 Primary outcomes in the methylprednisolone and standard care groups

	Methylprednisolone	Standard care	p-value
Subjects	34	28	
Time to event (discharge or death) days[#]	11.62±4.81	17.61±9.84	0.006*
Time to improvement days[#]	11.84±4.88	16.44±6.93	0.011*
Outcome			<0.001*
Recovery	32 (94.1)	16 (57.1)	
Death	2 (5.9)	12 (42.9)	

Data are presented as n or n (%), unless otherwise stated. [#]: median±range. *: p<0.05.




FIGURE 3 Kaplan–Meier estimator of survival rate between the methylprednisolone and standard care groups. Log-rank test: $p < 0.001$; hazard ratio 0.293 (95% CI 0.154–0.556).

3 days of treatment, and 10 out of 16 patients, at discharge time, did not need oxygen support (table 4). 19 out of 34 patients (55.8%) showed improvement and three out of 34 patients (8.8%) showed worsening in oxygen support status by 3 days of treatment in the methylprednisolone group, whereas six out of 28 patients (21.4%) showed improvement and 14 out of 28 patients (50%) showed worsening in the standard care group (supplementary figure S1). Patient status regarding oxygen support before and after treatment and the main outcome of each group are shown in supplementary figure S1.

To assess the percent of pulmonary involvement of patients in the methylprednisolone group, CT was performed at discharge time on 11 out of 31 discharged patients who agreed to give informed consent. The results showed that after treatment pulmonary involvement was improved 20–30% in eight out of the 11 patients and 50–60% in three out of the 11 patients (supplementary figure S2). CT scan findings and improvement in pulmonary involvement after treatment in a patient in the methylprednisolone group are shown in supplementary figure S3.

Laboratory findings

White blood cell count was significantly increased after 3 days of treatment and at discharge time in the methylprednisolone group, whereas it was not changed in the standard care group by 3 days of treatment and was only significantly increased at discharge time. Haemoglobin level and lymphocyte count were significantly decreased in the methylprednisolone group after 3 days of treatment and were restored at discharge time. We did not find a significant change in haemoglobin level and lymphocyte count in the standard care group before and after treatment. Although platelet count remained unchanged during treatment in the standard care group, it was significantly increased in the methylprednisolone group after treatment. VBG pH, HCO_3^- and PCO_2 levels remained unchanged until discharge time in the methylprednisolone group, whereas VBG HCO_3^- and PCO_2 levels were increased in the standard care group after treatment. Decreases in CRP and IL-6 levels were only shown in the methylprednisolone group after treatment. D-dimer, ferritin, LDH and CPK levels did not show any significant changes before and after treatment in either group of patients (table 5).

Safety and follow-up

Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study. There was one infection and one oedema adverse event in the methylprednisolone group, and two shock adverse events in the standard care group (supplementary table S1). All events and deaths during the study were judged by the site investigators to be unrelated to the intervention. In addition, no psychiatric or delirium events were detected in patients. Following the use of high-dose corticosteroids, most of the patients required insulin due to their known or hidden diabetes, and the insulin requirement was increased in the methylprednisolone group, especially in diabetic and overweight patients. However, the insulin

TABLE 4 Clinical characteristics of patients before and after treatment (analysed by repeated measures ANOVA)

	Before treatment		After treatment (day 3)				After treatment (discharge or death)			
	Methylprednisolone	Standard care	Methylprednisolone	p-value	Standard care	p-value	Methylprednisolone	p-value	Standard care	p-value
Borg score	7.7±1.7	7.1±2.6	4.8±2.2	<0.001*	6.2±3.4	0.154	1.7±0.8	<0.001*	1.8±1.8	0.001*
S_{po₂} %	82.1±5.7	83.6±4.7	88.1±6.1	<0.001*	80.5±8.3	0.03*	92.7±2.6	<0.001*	89.0±5.0	0.08
Systolic blood pressure mmHg	121.4±15.2	124.0±14.6	127.6±15.3	0.049*	122.8±20.0	0.544	126±14.0	0.009*	124.5±35.3	0.75
Diastolic blood pressure mmHg	76.1±9.4	75.3±7.7	78.0±8.8	0.28	74.0±14.2	0.76	74.7±9.0	0.54	74.0±8.2	0.33
Heart rate beats·min⁻¹	93.9±13.2	84.6±15.3	82.0±11.9	<0.001*	84.7±13.8	0.78	81.2±7.9	0.003*	85.9±17.7	0.41
Respiratory rate breaths·min⁻¹	23.7±4.6	21.4±4.5	20.8±3.1	0.001*	23.1±5.1	0.047*	18.6±2.4	<0.001*	21.0±3.8	0.89
Body temperature °C	37.3±0.9	37.2±0.8	36.7±0.4	0.001*	36.8±0.6	0.09	36.7±0.4	0.008*	36.8±0.3	0.29
GI symptoms	16 (47.1)	13 (46.4)	2 (5.9)	<0.001*	5 (17.9)	0.18	1 (3.1)	<0.001*	1 (6.3)	0.014*
Myalgia	17 (50.0)	15 (53.6)	4 (11.8)	0.001*	5 (17.9)	0.025*	0	<0.001*	1 (6.3)	0.025*
Chest pain	7 (20.6)	5 (17.9)	2 (5.9)	0.025*	2 (7.1)	0.16	1 (3.1)	0.014*	1 (6.3)	0.32
Cough	23 (67.6)	16 (57.1)	12 (35.3)	0.003*	12 (42.9)	0.16	6 (18.8)	<0.001*	6 (37.5)	0.32
Need for oxygen therapy	34 (100)	28 (100)	28 (82.4)	0.025*	26 (92.8)	0.56	6 (18.8)	<0.001*	6 (37.5)	0.003*

Data are presented as mean±SD or n (%), unless otherwise stated. S_{po₂}: arterial oxygen saturation measured by pulse oximetry; GI: gastrointestinal; NA: not available. *: p<0.05.

TABLE 5 Laboratory findings of patients before and after treatment (analysed by repeated measures ANOVA)

	Before treatment		After treatment (day 3)				After treatment (discharge or death)			
	Methylprednisolone	Standard care	Methylprednisolone	p-value	Standard care	p-value	Methylprednisolone	p-value	Standard care	p-value
WBC count ×10³ mg·L⁻¹	7.7±3.3	7.4±4.6	9.5±3.8	0.008*	8.1±4.6	0.36	10.5±4.9	0.002*	9.6±5.6	0.03*
Lymphocyte count mg·L⁻¹	1167±580	1171±632	804±345	<0.001*	1212±689	0.95	1085±667	0.77	1315±813	0.72
Haemoglobin g·dL⁻¹	13.0±1.7	14.7±6.0	12.1±2.1	0.007*	15.0±7.8	0.79	12.6±1.7	0.59	10.7±1.8	0.13
Platelet count ×10³ mg·L⁻¹	204±70	241±140	271±93	<0.001*	243±82	0.87	252±90	0.02*	193±127	0.88
VBG analysis										
pH	7.42±0.05	7.39±0.03	7.42±0.04	0.40	7.40±0.10	0.88	7.40±0.08	0.35	7.40±0.08	0.06
HCO ₃ mEq·L ⁻¹	25.5±4.7	22.9±6.4	26.4±4.6	0.73	27.4±1.6	0.011*	27.4±8.9	0.48	31.3±4.4	0.001*
P _{CO₂} mmHg	39.7±11.1	35.4±8.1	40.9±10.7	0.85	50.8±16.2	0.017*	45.4±16.4	0.39	NA	NA
CRP mg·L⁻¹	99.1±80.0	92.6±70.3	40.8±30.6	<0.001*	91.9±68.0	0.66	30.6±23.1	0.001*	77±83.0	0.20
ESR mm·h⁻¹	64.2±27.1	57.4±32.8	50.9±35.3	0.11	57.0±33.6	0.86	55.7±22.6	0.09	80.0±25.7	0.77
IL-6 pg·mL⁻¹	76.3±85.0	79.3±60.9	15.9±22.9	<0.001*	32.5±6.5	0.160	3.9±9.1	0.001*	NA	NA
D-dimer ng·mL⁻¹	2573±2668	1391±1751	2155±1441	0.41	2131±2252	0.25	1762±830	0.16	NA	NA
Ferritin ng·mL⁻¹	808±521	677±463	766±400	0.17	777±467	0.62	275±303	0.18	476±219	0.28
LDH U·L⁻¹	672±286	645±179	897±558	0.74	706±453	0.91	633±153	0.49	NA	NA
CPK U·L⁻¹	159±152	214±209	249±154	0.78	NA	NA	85±203	0.81	NA	NA

Data are presented as mean±SD, unless otherwise stated. WBC: white blood cell; VBG: venous blood gas; P_{CO₂}: partial pressure of carbon dioxide; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IL: interleukin; LDH: lactate dehydrogenase; CPK: creatine phosphokinase; NA: not available. *: p<0.05.

requirement level was controlled by physicians and returned to normal at discharge time and there were no adverse events according to uncontrolled diabetes in patients. Borg score and clinical characteristics of recovered patients (n=48) were assessed 1 week after discharge time. Borg score was significantly diminished 1 week after discharge time in both groups. None of the patients in the methylprednisolone group had gastrointestinal symptoms, myalgia or chest pain after discharge. Two patients in the standard care group still had gastrointestinal symptoms and myalgia after discharge. Six out of 32 patients (18.8%) in the methylprednisolone and three out of 16 patients (18.8%) in the standard care group still had cough 1 week after discharge (supplementary table S2).

Discussion

The current study is the first randomised controlled trial to evaluate changes in clinical symptoms and laboratory signs of COVID-19 patients by methylprednisolone therapy. The study found that methylprednisolone pulse administration at the beginning of the early pulmonary phase of illness remarkably decreased the mortality rate and improved pulmonary involvement, S_{pO_2} , and inflammatory markers in COVID-19 patients. Given the increased incidence and mortality of COVID-19 across the world, the helpful and effective treatment for patients in the early pulmonary phase is still of paramount importance. There have been some reports surrounding beneficial [11] or harmful evidence [18, 19] of corticosteroid therapy during previous SARS and MERS outbreaks, but the reports are not conclusive [20]. However, the clinical evidence for the efficacy of receiving corticosteroids in COVID-19 patients and the time for administration are undetermined.

The current study enrolled a severely ill population of COVID-19 patients in the early pulmonary phase (not intubated). The mortality rate was observed to be significantly lower among patients treated with methylprednisolone than patients treated with standard care. 94.1% of patients in the methylprednisolone group had recovered by a median duration of 11.8 days. However, only 57.1% of patients in the standard care group had recovered by a median duration of 16.4 days. Methylprednisolone treatment was related to the shorter time to event in patients and survival analysis showed that the patients in the methylprednisolone group had a significantly decreased death hazard rate compared with the patients in the standard care group.

The effect of dexamethasone on the clinical symptoms of hospitalised COVID-19 patients was studied in the clinical trial by the RECOVERY Collaborative Group [21]. A total of 2104 patients received dexamethasone and 4321 received standard care. Their results showed that the incidence of death was significantly lower in patients receiving oxygen support and invasive mechanical ventilation. In our study, all patients received oxygen support and none of them received mechanical ventilation; however, in line with the RECOVERY trial, the incidence of death was significantly lower in patients receiving NIV and reservoir mask support in the methylprednisolone group (7.7% and 8.3%, respectively) compared with the standard care group (60.0% and 57.1%, respectively). In addition, some observational studies report recent clinical findings on the administration of corticosteroids in the treatment of COVID-19 [22]. Some studies did not find significant benefits of corticosteroid admission and reported that pulmonary involvements caused by SARS-CoV-2 were not inhibited by corticosteroid treatment [23–25]. However, it was also reported that the administration of corticosteroid for patients with ARDS resulted in a reduced risk of death [26]. The observed differences could be due to the differences in the amount and duration of treatment, small sample size, age of patients, and severity of the disease. The clinical and laboratory characteristics and pulmonary involvements of patients were not fully determined and reported in those observational studies. It seems that the administration time and pulmonary phase of patients are key factors in corticosteroid treatment efficacy.

In our study, patients in the methylprednisolone group had a faster improvement in S_{pO_2} , Borg score and dyspnoea. Improvement and worsening in oxygen support status were observed in 55.8% and 8.8%, respectively, of patients in the methylprednisolone group by day 3 of treatment, whereas in the standard care group only 21.4% of patients showed improvement in oxygen support and 50% showed worsening. Our results show that patients in the methylprednisolone group were less likely to receive invasive ventilation. Only 8.8% of patients in the methylprednisolone group received invasive ventilation, whereas in the standard care group, 32.1% of patients received mechanical ventilation after treatment. In line with our results, in a cohort study by WANG *et al.* [27], it was demonstrated that patients with methylprednisolone treatment had a faster improvement of S_{pO_2} , decrease in CRP and IL-6 levels, and were less likely to receive invasive ventilation. However, WANG *et al.* [27] did not observe significant differences in mortality rate between groups.

Our results also showed that corticosteroid therapy can improve ventilation in patients. VBG analysis showed an increase in HCO_3 and PCO_2 levels in the standard care group, which can indicate respiratory

acidosis and decreased ventilation in patients [28], whereas VBG markers did not change significantly in the methylprednisolone group.

The clinical characteristics of patients, including heart rate, respiratory rate and temperature, were also significantly improved in the methylprednisolone group, whereas they did not change or worsen in the standard care group during treatment. Gastrointestinal symptoms and myalgia were improved in patients from both groups, whereas chest pain and cough were only significantly improved in the methylprednisolone group. Intravenous methylprednisolone administration increased blood pressure in patients, which is due to the hypertensive side-effects of glucocorticoids [29].

It has been demonstrated that elevated serum levels of IL-6 and CRP as inflammatory markers are associated with the severity of COVID-19 and can be used as a predictive factor for disease risk [30]. Patients included in this trial had increased CRP and IL-6 serum levels at enrolment. A significant decrease in the serum levels of these inflammatory markers was shown only in the methylprednisolone group after treatment.

Previous studies reported that corticosteroid administration can increase the risk of post-treatment infection in viral disease; however, in our study the incidence of nosocomial infections was very low in both the methylprednisolone and standard care groups. Improved patients were followed-up for 7 days after treatment and clinical symptoms remained unchanged. We will continue to follow-up the patients, and CT scans, spirometry and pulse oximetry will be performed for 6 weeks after improvement to evaluate their long-term prognosis.

Conclusions

In this study, we assessed the intravenous methylprednisolone effect on the treatment of patients with severe COVID-19. Clinical data showed that methylprednisolone administration at the beginning of the early pulmonary phase of illness remarkably improved pulmonary involvement, oxygen saturation, dyspnoea, heart rate, respiratory rate, temperature and inflammatory markers (e.g. CRP and IL-6 serum levels) in patients, suggesting that methylprednisolone could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase. Unfortunately, we could not collect viral load data to assess the effects of methylprednisolone on viral load changes between baseline and discharge time. There are several other limitations in this study, including the possible existence of bias, single-blind design of the study, lack of follow-up to identify late adverse events (e.g. hip osteonecrosis or tuberculosis re-activation) and limited sample size. Further studies need to be undertaken.

Data sharing: Data are available on request from the corresponding author.

Author contributions: M. Edalatfard, M. Salehi, Z. Naderi, S.R. Najafzadeh, N. Jalili, M. Esfahani, B. Rahimi, H. Kazemzadeh, T. Ghazanfari, H. Ebrahimi Louyeh, S.R. Raeeskarami, S. Jamalimoghadamsiahkali and N. Khajavirad: acquisition of clinical data and patient diagnosis and treatment, interpretation of data, drafting the article, and final approval of the article. M. Mahmoodi Aliabadi and M. Sattarian: acquisition of laboratory data, interpretation of data, drafting the article and final approval of the article. M. Akhtari, A. Jamshidi, S. Mostafaei, E. Farhadi, M. Mahmoudi and A. Rostamian: conception and design of the study, analysis and interpretation of data, revising the article critically for important intellectual content, and final approval of the article.

Conflict of interest: None declared.

Support statement: This study was supported by a grant from the Deputy of Research, Tehran University of Medical Sciences (grant 99-1-101-47282). The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

References

- 1 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun* 2020; 109: 102433.
- 2 de Wit E, van Doremalen N, Falzarano D, *et al.* SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol* 2016; 14: 523–534.
- 3 Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J Med Virol* 2020; 92: 441–447.
- 4 Guan WJ, Ni ZY, Hu Y, *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382: 1708–1720.
- 5 Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? *Arab J Gastroenterol* 2020; 21: 3–8.
- 6 Shi Y, Wang Y, Shao C, *et al.* COVID-19 infection: the perspectives on immune responses. *Cell Death Differ* 2020; 27: 1451–1454.
- 7 Chen N, Zhou M, Dong X, *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395: 507–513.

- 8 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506.
- 9 Mehta P, McAuley DF, Brown M, *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; 395: 1033–1034.
- 10 Buttgerit F, Straub RH, Wehling M, *et al.* Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. *Arthritis Rheum* 2004; 50: 3408–3417.
- 11 Sung JY, Wu A, Joynt GM, *et al.* Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004; 59: 414–420.
- 12 Tsang OTY, Chau TN, Choi KW, *et al.* Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. *Emerg Infect Dis* 2003; 9: 1381–1387.
- 13 Arabi YM, Mandourah Y, Al-Hameed F, *et al.* Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med* 2018; 197: 757–767.
- 14 Moher D, Hopewell S, Schulz KF, *et al.* CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010; 340: c869.
- 15 Ding Z, Li X, Lu Y, *et al.* A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. *Respir Med* 2016; 121: 39–47.
- 16 Bigler D, Jonsson T, Olsen J, *et al.* The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations. *J Thorac Cardiovasc Surg* 1996; 112: 142–145.
- 17 Muir J, Godard P, Leophonte P, *et al.* Seventy-two hour comparison of methylprednisolone sultepanate and methylprednisolone sodium succinate in patients with acute asthma. *Br J Clin Pract* 1996; 50: 440–445.
- 18 Lee N, Allen Chan KC, Hui DS, *et al.* Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. *J Clin Virol* 2004; 31: 304–309.
- 19 Lee DT, Wing YK, Leung HC, *et al.* Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. *Clin Infect Dis* 2004; 39: 1247–1249.
- 20 Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006; 3: e343.
- 21 RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. *N Engl J Med* 2020; in press [<https://doi.org/10.1056/NEJMoa2021436>].
- 22 Veronese N, Demurtas J, Yang L, *et al.* Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. *Front Med* 2020; 7: 170.
- 23 Liu K, Fang YY, Deng Y, *et al.* Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J* 2020; 133: 1025–1031.
- 24 Ling Y, Xu S-B, Lin Y-X, *et al.* Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J* 2020; 133: 1039–1043.
- 25 Zha L, Li S, Pan L, *et al.* Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Med J Aust* 2020; 212: 416–420.
- 26 Wu C, Chen X, Cai Y, *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020; 180: 934–943.
- 27 Wang Y, Jiang W, He Q, *et al.* A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. *Signal Transduct Target Ther* 2020; 5: 57.
- 28 Epstein SK, Singh N. Respiratory acidosis. *Respir Care* 2001; 46: 366–383.
- 29 Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. *Pediatr Nephrol* 2012; 27: 1059–1066.
- 30 Liu F, Li L, Xu M, *et al.* Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; 127: 104370.